In This Section

Coronavirus Series – Part 1:
Antiviral Measures Targeting Coronavirus Entry

Thursday, July 30, 2020, 1:00 pm – 2:30 pm ET

COVID-19 first began in late 2019 and as of July 2020 approximately 12 million people have been infected with a mortality rate of over 4% globally.  The SARS-CoV-2 virus is differentiated from the many common coronavirus variants, including those associated with the common cold, by its cross-species infectivity, rapid spread, and lethality.  Rapid advances in the identification of this new coronavirus,  and its putative host susceptibility factor, angiotensin converting enzyme 2 (ACE2) as the SARS-CoV-2 cell surface receptor, have led to the proliferation of clinical drug repurposing and preclinical rational drug design efforts to combat this devastating pandemic. 

Dr. Thomas Gallagher is a leading expert on the virology of coronaviruses.  His talk will provide an overview of the virology of coronaviruses, the current understanding of SARS-CoV-2 viral entry and provide critical insights regarding various interventional strategies to limit infectivity.  Given the ongoing societal and economic impact of COVID-19 pandemic world-wide, this seminar will be of great interest to all ASPET members.

Moderators:

Michael F. Jarvis, PhD, FBPhS - AbbVie
Qing Ma, PharmD, PhD – University at Buffalo

Speaker:

Thomas Gallagher, PhD
Loyola University Chicago, Department of Microbiology and Immunology


Coronavirus Series – Part 2:
Therapeutic Research for COVID-19:  Challenges and Accomplishments

Wednesday, August 19, 2020, 1:00 pm – 2:15 pm ET

The clinical evaluation of potential therapeutic options against COVID-19 has largely been conducted within the context of limited bandwidth and an escalating world-wide health-care crisis.  To date, many studies of clinical interventions are anecdotal reports of effects in small numbers of patients or larger observational cohort studies that also contain uncontrolled confounders.

Dr. H. Clifford Lane is the NIAID Deputy Director for Clinical Research and Special Projects.  His talk will provide an overview of several potential antiviral and immunomodulatory COVID-19 interventions that have been studied in large-scale randomized clinical trials including mechanistic rationale, clinical trials designs and endpoints, and emerging benefit/risk profiles.  Given the ongoing societal and economic impact of COVID-19 pandemic world-wide, this seminar will be of great interest to all ASPET members.

Speaker:

H. Clifford Lane, MD
National Institute of Allergy and Infectious Diseases, NIH

 

Last Updated: September 3, 2020

Job Postings